AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the company’s plan to invest $50 billion in the U.S.

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

One of Trump's demands was that the CEOs' companies limit drug costs for states' Medicaid plans to "most-favored nation" ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

President Donald Trump has given major pharmaceutical companies 60 days to slash prescription drug prices or face action.

Plus: All the news and watercooler chat from Fortune.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...